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I. INTRODUCTION 
In rat adipose tissue, the lipolytic activity is nega- 
tively controlled by various structurally unrelated 
biological compounds[ 11. Some of them are endo- 
genous substances released by the cells, such as 
adenosine 121, prostaglandins E2 and F2 (Y (PGE2, 
PGF2 a) [3] and prostacyclin (PGI2) [4,5]; others, as 
insulin, belong to the endocrine pancreatic system. 
The physiological significance of adenosine, an end 
degradation product of cyclic AMP is well estab- 
lished [6-81 whereas the efficiency of the negative 
feedback of endogenous prostaglandins is not con- 
vincingly demonstrated [9, lo] and has been ques- 
tioned [ 111. 
The sites of action of insulin are double and ex- 
press themselves in the increase of phosphodiester- 
ase activity [ 12- 141 and in the inhibition of aden- 
ylate cyclase activity [15-171. The mechanism of 
the former effect of insulin is unknown but that of 
the latter implicates the participation of endo- 
genous prostanoids [ 181. Actually, insulin increases 
the sensitivity of adenylate cyclase to the inhibitory 
action of prostaglandins. 
The aim of our work was to find the site of action 
of the mentioned antilipolytic substances. Fat cells or 
adipose tissue were exposed to the action of cholera 
toxin which activates irreversibly the adenylate 
cyclase system [ 191 via an inhibition of GTPase 
activity [20]. Here, we show that this treatment 
suppresses the inhibitory action of N6-(phenylisopro- 
pyl) adenosine (PIA) (a non-metabolizable analog 
of adenosine), of PGEl and PGI2 and of insulin on 
free fatty acids release and cyclic AMP production. 
These results suggest that these effecters share a 
common pathway at the guanosine triphosphatase 
(GTPase) level. 
2. MATERIALS AND METHODS 
Crystalline bovine insulin B-grade (25.5 IU/ mg) 
and collagenase (200 U/mg, Worthington Bio- 
chemical Corp.) were purchased from Calbio- 
them. L-Adrenaline bitartrate (lot 4-4375) and D,L- 
isoproterenol-HCl (lot l-5627) were obtained from 
Sigma as was Bovine serum albumin fraction V, 
which was purified from fatty acids according to 
[21]. I-Methyl-3-isobutyl xanthine (IBMX) (lot 
1353) was obtained from Regis and 3-(3, 4 di- 
methoxybenzyl-2-imidazolidinone (RO 7-2956) 
was kindly donated by Hoffman-La Roche (Basel). 
N6-(phenylisopropyl) adenosine (PIA) was 
obtained from Boerhinger. Prostaglandins E 1, F 1” 
and prostacyclin were a gift from the Upjohn Co. 
(Kalamazoo MI) and cholera toxin (23.2 LB/pg 
protein was a gift from Professor Dodin, Institut 
Pasteur, Paris). 
Male Wistar rats (180 g) were obtained from 
Animalabo (Paris), kept at room temperature and 
given free access to food and water. 
Rats were decapitated and the epididymal fat 
pads were removed as quickly as possible, rinsed in 
the ice-cold saline (NACl 0.9%, w/v). The fat pads 
were cut in small fragments (80-100 mg), and 
distributed among vials containing Krebs Ringer 
bicarbonate buffer 0.1 M (pH 7.4) with half the 
recommended [Ca’+] (1.3 mM) and 4% (w/v) fatty 
acid free albumin. White fat cells were isolated by 
collagenase digestion as in 1221. 
Hormones and drugs were made up freshly in 
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buffer to the required final concentrations. Prosta- 
cyclin was dissolved in 0.05 M Tris buffer (pH 9) 
and immediately added to the incubate. IBMX and 
RO 7-2956 were dissolved in dimethyl sulfoxide 
which has no effect on lipolysis by itself at the con- 
centration used. Tissues or fat cells were preincu- 
bated for 2 h at 37°C with or without cholera toxin 
and then placed in fresh medium containing the 
appropriate hormone(s) and drug(s) for different 
intervals: 1 h for the studies of lipolysis (free fatty 
acids release) or 6 min for cyclic AMP production. 
Free fatty acids were extracted as in 1231 and 
determined as in 1241. 
Glycerol was measured as in [25]. Triglycerides 
were extracted as in [26]. Portions of total lipid 
extracts were saponified in KOH 4% (w/v) in 95% 
(v/v) ethanol for 30 min at 60°C. Glycerol was 
measured as above. 
Cyclic AMP was assayed by the radioimmuno- 
logical method in [27] except that bound ligand was 
separated from the ligand by polyethylene glycol 
precipitation (P. Mayeux, unpublished). 
The statistical differences were calculated with 
Fig.1. Effect of N6-(phenylisopropyl) adenosine on iso- 
proterenol and RO 7-2956 stimulated lipolysis in the 
presence and the absence of cholera toxin. Relationship 
between cyclic AMP and free fatty acid release. Results 
are given as means f SEM calculated from 6 prep. fat 
cells. Significance of effect of drug: *P < 0.001; **P = 
NS. Abbreviations: B, control values; PIA, N6-(phenyliso- 
propyl) adenosine (10 -6 M); CT, cholera toxin (5 rg/ 
ml); RO, RO 7-2956 (10 -3 M); IPNE, isoproterenol 
Fig.2. Effect of prostaglandin El (10 -6 M) on cyclic AMP 
(fat tissue) and free fatty acid release (fat cells) on iso- 
proterenol (10 -6 M) and 3-isobutyl-1-methylxanthine 
(10 -3 M) in the presence and the absence of cholera toxin 
(5 pg/ml). Results are given as the mean + SEM of 6 
assays respectively. Significance of effect of hormone: 
(10 -6 M). * P <O.OS; ** P = NS. 
Student’s_t-test. The mean values are expressed 
with standard error of the mean (SEM). 
3. RESULTS 
3.1. Conditions of cholera toxin treatment 
The maximal effective concentration of cholera 
toxin was of 5 pg/ml for 3 h incubation. With this 
concentration, after a lag period of 30 min, the rate 
of cyclic AMP accumulation, free fatty acid release 
and glycerol production was constant with an aver- 
age doubling time of 1 h (not shown). 
In the subsequent experiments, tissue or cells 
were preincubated with cholera toxin at 5 pg/ml for 
2 h when indicated, then incubated in the presence 
of the various effecters and cholera toxin as in sec- 
tion 2. 
3.2. Effect of cholera toxin treatment on PIA anti- 
lipolytic action 
In these experiments, phosphodiesterase activity 
was inhibited with RO 7-2956 (10 -3 M) to allow a 
constant rate of cyclic AMP accumulation and to 
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Fig.3. Effect of prostacyclin 12 (10 ~ ’ M) on cyclic AMP 
and free fatty acid release on isoproterenol(l0 - 6 M) and 
3-isobutyl-I-methylxanthine (10 - 3 M) in the presence 
and absence of cholera toxin (5 &ml) in rat adipocytes. 
Results are given as the mean 2 SEM of 6 assays, 
respectively. Significance of effects of hormone: 
*P < 0.001; **P = NS. 
prevent interference at the adenosine receptor level 
with IBMX. Adenylate cyclase was stimulated by 
isoproterenol(10 - 6 M). 
Results in fig. 1 show the complete suppression of 
the inhibitory action of PIA (10 - 6 M) on cyclic 
AMP accumulation and on the release of free fatty 
acids. 
3.3. Effect of cholera toxin treatment on the anti- 
lipolytic activity of prostanoids 
PGEt (10 - 6 M) fig.2 and PG12 (10 - ’ M) 
fig.3 inhibited cyclic AMP accumulation and lipo- 
lysis stimulated by isoproterenol (10 ~ 6 M) with 
ZCsu values of 3 x lo-’ M and 3 x 10V8 M, 
respectively (not shown). 
When tissues or cells were preincubated and then 
incubated with cholera toxin, inhibition by prosta- 
noids no longer occurred. In these experiments 
PDE activity was inhibited with IBMX (10 - 3 M). 
Neither PGF2rr nor 6-keto prostaglandin Ftn were 
active (not shown). 
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Fig.4. Effect of insulin (100 $/ml) on cyclic AMP and 
free fatty acid release on isoproterenol (10 - 6 M) and 
3-isobutyl- I-methylxanthine (10 - 3 M) in the presence 
and absence of cholera toxin (5 pg/ml) in rat adipocytes. 
Results are given as the mean -C SEM of 6 assays, 
respectively. Significance of effects of hormone: 
*P < 0.05; **P = NS. 
3.4. Effect of cholera toxin treatment on the anti- 
lipolytic activity of insulin 
Incubations were performed in the presence of 
adrenaline (5 x 10 - 6 M) and of IBMX (10 - 3 M). 
The inhibition of phosphodiesterase activity allows 
a constant rate of accumulation of cyclic AMP and 
prevents the anti-lipolytic action of insulin at the 
PDE level. Under these conditions, the inhibitory 
action of insulin at the adenylate cyclase level dis- 
appeared when the tissues have been initially 
exposed to cholera toxin (ftg.4). Neither the 
cyclic AMP content nor the free fatty acid release 
were depressed under these conditions. 
4. DISCUSSION 
Prostanoids (PGE 1 and PGI2) as well as PIA and 
insulin at the concentration used showed antilipo- 
lytic activities either at the adenylate cyclase or at 
the phosphodiesterase levels or both in rat fat adi- 
pose tissue. Our present aim was to study the effect 
of these structurally different substances on the stim- 
ulated adenylate cyclase activity in the presence 
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of inhibitors of the PDE activity and in the presence 
or in the absence of cholera toxin. In rat adipose 
tissue or fat cells, there is evidence that cholera 
toxin accelerates lipolysis and cyclic AMP produc- 
tion [28-311 by maintaining the adenylate cyclase 
activity in a constant activated state (201 through the 
inhibition of the GTPase activity. 
Our results showed that the treatment of fat cells 
or tissue with cholera toxin prior to stimulation with 
/I-adrenergic effecters, suppresses the antilipolytic 
action of PGEt, or PGI2 and of PIA as described by 
1321 and of insulin. The inhibitory effects of these 
substances at the level of cyclic AMP is also sup- 
pressed. A similar behavior of cholera toxin against 
the 4 effecters was now observed, suggesting that 
they share the same mode and probably the same 
site of action. This confirms the results [33] for PGE 
and PIA but is new for insulin and furthermore 
brings additional support for the evidence of a site 
of action located at the adenylate cyclase level. 
Several hypotheses may explain the mode of action 
of cholera toxin. Since cholera toxin inhibits the 
GTPase activity of the adenylate cyclase system [3 1] 
PGEt, PGI2, PIA and insulin may be antilipolytic 
by increasing the GTPase activity; the enhanced 
hydrolysis of GTP in turn, would inactivate the 
catalytic subunit of the cyclase and then reduce the 
rate of synthesis of cyclic AMP and the efficiency of 
lipolysis. This hypothesis is reinforced since adeno- 
sine has been described as mediating the stimula- 
tion of GTP hydrolysis in adipocyte membranes 
[34]. We cannot discard an alternative explanation 
[35] suggesting that adenosine and PGE increase 
the displacement rate of GDP from the regulatory 
subunit of adenylate cyclase. The mechanism(s) by 
which these antilipolytic compounds achieve their 
effects is far from clear and further experiments are 
necessary to elucidate this problem. 
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